Hyperphosphatemia

60% of End Stage Renal Disease (ESRD) patients suffer from hyperphosphatemia (elevated blood phosphorus levels) as their kidneys are no longer able to filter out the phosphates present in every day food. Dialysis also does not fully remove all phosphorus from the body. Elevated levels of phosphorus are associated with calcification of artery walls, heart valves and joints, bone pain and bone deformity and may result in death.

Kemira’s calcium acetate is an Active Pharmaceutical Ingredient in so-called phosphate binders which are used to reduce the absorption of phosphate into the human body. Calcium acetate combines with phosphates present in most foods and drinks and forms insoluble calcium phosphate complexes that are eliminated from the body. This reduces phosphorus absorption by the body and lowers the phosphorus levels of the blood.

Kemira’s pharmaceutical grade products are subject to rigid quality control to ensure very high purity, fulfilling all the required specifications of various pharmacopoeias.